Company news

Noxopharm Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

US company demonstrates strong Sofra potential

August 4, 2025

June 2025 Quarterly Activities Report and Appendix 4C

July 29, 2025

HERACLES clinical trial - Update 1

July 28, 2025

First SOF-SKN dose in HERACLES clinical trial

July 15, 2025

Promising Sofra results from overseas company

June 11, 2025

Green light for HERACLES clinical trial

May 28, 2025

New funds from Nyrada share sales

May 19, 2025

March 2025 Quarterly Activities Report and Appendix 4C

April 29, 2025

Appendix 4D and FY2025 Half Year Financial Report

February 25, 2025

SOF-SKN passes required in vitro safety tests

February 3, 2025

December 2024 Quarterly Activities Report and Appendix 4C

January 28, 2025

Additional convertible note for long-term shareholder

November 4, 2024

September 2024 Quarterly Activities report and Appendix 4C

October 28, 2024

New funding from sophisticated investors

September 27, 2024

Advanced funding secured ahead of R&D rebate

September 5, 2024

Significant results from new brain cancer drugs

September 2, 2024

Noxopharm Targets Clinical Trial for First-in-Class Drug

August 19, 2024

Significant CRO-67 Results in Pancreatic Cancer Studies

August 14, 2024

June 2024 Quarterly Activities Report and Appendix 4C

July 22, 2024

March 2024 Quarterly Activities Report and Appendix 4C

April 28, 2024

Appendix 4D and Half Year 2024 Financial Report

February 26, 2024

December 2023 Quarterly Activities Report and Appendix 4C

January 22, 2024

Noxopharm Enhances Cash Position via R&D Rebate

November 15, 2023

Noxopharm 2023 AGM Corporate Presentation

November 15, 2023

mRNA Vaccine Enhancer Shows Inflammation Reduction

October 17, 2023

September 2023 Activities Report and Appendix 4C

October 12, 2023

Response to ASX Query

October 8, 2023

US FDA grants Orphan Drug Designation for CRO-67

October 3, 2023

Trading Halt

October 3, 2023

Pause in Trading

October 3, 2023

Latest CRO-67 data shows success in reducing cancer growth

September 27, 2023

Appendix 4E and Audited Financial Statements

August 31, 2023

June 2023 Activities Report and Appendix 4C

July 13, 2023

IONIC Trial Abstract Published at ASCO

May 25, 2023

Study results show new Sofra drug reduces inflammation

May 18, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 23, 2023

Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs

April 5, 2023

Noxopharm Announces Novel mRNA Vaccine Enhancer

March 27, 2023

Appendix 4D and Half Year 2023 Financial Report

February 24, 2023

December 2022 Quarterly Activities Report and Appendix 4C

January 26, 2023

DARRT-2 Trial Efficacy Phase to Commence

January 16, 2023

NOX Pipeline Boosted by $1.5M Grant to Hudson Institute

December 15, 2022

September 2022 Quarterly Activities Report and Appendix 4C

October 20, 2022

Novel Dual-cell Therapy Results in Pancreatic Cancer

September 13, 2022

Response to ASX Price Query

September 1, 2022

June 2022 Quarterly Activities Report and Appendix 4C

July 26, 2022

March 2022 Quarterly Activities Report and Appendix 4C

April 27, 2022

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

March 29, 2022

Orphan Drug Designation Granted to Noxopharm by US FDA

March 21, 2022

First Patient Treated in CEP-2 Sarcoma Trial

February 27, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 53 decks. Every deck is listed under its year.